Coombes RC, Tovey H, Kilburn L, et al. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). SABCS 2017, GS3-03.
Europese goedkeuring pembrolizumab bij NSCLC met tumor-PD-L1 expressie ≥ 50%
feb 2017 | Longoncologie